Recurrent mutations in the NRXN1 gene have been identified in individuals with ASD as described below. Numerous studies have demonstrated a statistically significant enrichment of NRXN1 deletions in ASD cases compared to controls [10 in 2195 cases vs. none in 2519 controls (permuted P-value 0.002) in Glessner et al., 2009; 9 in 1771 cases vs. none in 2539 controls (P-value 3.3 E-04) in Bucan et al., 2009; an excess of exonic NRNX1 CNVs in 996 cases compared to 4,964 controls ((P-value 7.7E-4) in Pinto et al., 2010; 7 exonic deletions in 2,588 cases vs. 1 in 2,670 controls (P-value 0.032) in Girirajan et al., 2013]. A similar enrichment of NRXN1 deletions have been repeatedly observed in cohorts composed of cases with a spectrum of neurodevelopmental disorders, including ASD [9 exonic NRXN1 deletions in 3,540 cases vs. 10 in 51,939 controls (P-value 8.9E-07) in Ching et al., 2010; exonic NRXN1 deletions observed in 0.11% of cases compared to 0.02% of controls (P-value 6.08E-07) in Dabell et al., 2013; NRXN1 deletions in 30 cases vs. 9 controls (simulated P-value of 0.00005) in Coe et al., 2014; P<0.0001 in 19,263 cases and 15,264 controls in Lowther et al., 2016]. Multiple studies have also reported point mutations in NRXN1 in individuals with ASD (Feng et al., 17034946; Kim et al., 2008; Yan et al., 2008; Duong et al., 2012; Liu et al., 2012; Camacho-Garcia et al., 2012), including de novo loss-of-function variants in two probands from simplex families (Iossifov et al., 2012; Stessman et al., 2017). Biallelic mutations in NRXN1 have also been implicated in Pitt-Hopkins-like syndrome 2, an autosomal recessive intellectual disability syndrome (Zweier et al., 2009; Harrison et al., 2011). A polymorphism located in the 3' UTR of NRXN1 was found to influence white matter volume and sensorimotor function in a cohort of healthy individuals in Voineskos et al., 2011 (PMID 21687627).
Molecular Function
Neurexins function in the vertebrate nervous system as cell adhesion molecules and receptors. Two neurexin genes are among the largest known in human (NRXN1 and NRXN3). By using alternate promoters, splice sites and exons, predictions of hundreds or even thousands of distinct mRNAs have been made.
External Links
References
Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
High frequency of neurexin 1beta signal peptide structural variants in patients with autism.
Neurexin 1 (Nrx-1) is a transmembrane synaptic adhesive molecule. It regulates the synaptic architecture and function in the brain and neuromuscular junction. Neurexin-1 roles include synaptic growth, transmission, synaptic formation and also regulation of learning and memory, locomotion and visual function. Reduced nighttime sleep in neurexin mutants is due to impaired neuronal output. Neurexin functionally couples calcium channels (Cac) to regulate synaptic transmission. Nrx-1 transcripts are enriched in brain and ventral nerve cord neurons starting at embryonic stage 14 and are absent from muscle. They are also detected in small subsets of peripheral nervous system neurons. Nrx-1 transcripts are enriched in brain and ventral nerve cord neurons starting at embryonic stage 14 and are absent from muscle. They are also detected in small subsets of peripheral nervous system neurons.
References
Type
Title
Author, Year
Primary
Neurexin-1 regulates sleep and synaptic plasticity inDrosophila melanogaster.
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Nrx-1^313 mutant contains a 10bp deletion of a highly conserved sequence at intron 7 that has been suggested to represent an essential regulatory region. This mutation was generated by mobilization of P{Mi}Nrx-1{MB00002} and using the PhsILMiT transposase. Nrx-1^313 mutants were selected based on loss/ alteration in minos element eGFP expression (indicating that the transposon had changed location) and loss of neurexin immunoreactivity (PMID 20559439). Nrx-1^214 contains a precise deletion of the coding region; this mutant was identified by selecting third-instar larvae without GFP expression (PMID 17785181). The two alleles were combined in double heterozygous mutant.
Allele Type: Loss-of-function
Strain of Origin: Unreported
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439); Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Nrx-1^273 has an ~8kb deletion that removes most of the coding sequence for the extracellular region of Drosophila Nrx-1; this mutant was identified by selecting third-instar larvae without GFP expression (PMID 17785181). Nrx-1^313 mutant contains a 10bp deletion of a highly conserved sequence at intron 7 that has been suggested to represent an essential regulatory region. This mutation was generated by mobilization of P{Mi}Nrx-1{MB00002} and using the PhsILMiT transposase. Nrx-1^313 mutants were selected based on loss/ alteration in minos element eGFP expression (indicating that the transposon had changed location) and loss of neurexin immunoreactivity (PMID 20559439). The two alleles were combined in double heterozygous mutant.
Allele Type: Loss-of-function
Strain of Origin: Unreported
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^273 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181); David Featherstone
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Deficiency (Df) mutation containing a chromosomal deletion including Nrx-1. Nrx-1^214 contains a precise deletion of the coding region; this mutant was identified by selecting third-instar larvae without GFP expression (PMID 17785181). The two alleles were combined in double heterozygous mutant.
Allele Type: Loss-of-function
Strain of Origin: Unreported
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Deficiency (Df) mutation containing a chromosomal deletion including Nrx-1. Nrx-1^313 mutant contains a 10bp deletion of a highly conserved sequence at intron 7 that has been suggested to represent an essential regulatory region. This mutation was generated by mobilization of P{Mi}Nrx-1{MB00002} and using the PhsILMiT transposase. Nrx-1^313 mutants were selected based on loss/ alteration in minos element eGFP expression (indicating that the transposon had changed location) and loss of neurexin immunoreactivity (PMID 20559439). The two alleles were combined in double heterozygous mutant.
Allele Type: Loss-of-function
Strain of Origin: Unreported
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Pan-neuronal driver appl-GAL4 was used to drive over-expression of full length UAS-Nrx-1.
Allele Type: Overexpression
Strain of Origin: w^1118
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439); Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Pan-neuronal driver elav-GAL4 was used to drive over-expression of full length UAS-Nrx-1.
Allele Type: Overexpression
Strain of Origin: w^1118
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439); Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Pan-neuronal driver elav^c155-Gal4 was used in combination with Gal4 repressor Gal80^ts to control the timing of Nrx-1 overexpression.
Allele Type: Overexpression
Strain of Origin: w^1118
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439); Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Heterozygous/heterozygous
Mutation:
Pan-neuronal driver elav^c155-Gal4 was used in combination with Gal4 repressor Gal80^ts to control the timing of Nrx-1 overexpression.
Allele Type: Overexpression
Strain of Origin: w^1119
Genetic Background: ES Cell Line: Mutant ES Cell Line: Model Source: Nrx-1^313 provided by David Featherstone (University of Illinois at Chicago; PMID 20559439); Nrx-1^241 provided by Manzoor Bhat (Department of Cell and Molecular Physiology, UNC-Neuroscience Center and Neurodevelopmental Disorders Research Center, University of North Carolina School of Medicine; PMID 17785181)
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
.
Allele Type: Loss-of-function
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source: Bloomington Drosophila Stock Center
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
.
Allele Type: Loss-of-function
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source: Bloomington Drosophila Stock Center. Rongwen Xi (National Institute of Biological Sciences, Beijing)
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
.
Allele Type: Loss-of-function
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source: Ronald L. Davis (The Scripps Research Institute, Jupiter, FL)
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between 104Y-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c305a-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c309-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c316-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
c739-Gal4 driver line expressing UAS-Nrx^RNAi in the background of tub-Gal80^ts. Flies allowed to develop normally with neurxin but then shifted to 30C in adulthood to block neurexin synthesis.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c739-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c819-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between c929-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between llp-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between MB247-Gal4 line and UAS-neurexin RNAi line to generate neurexin mutants in specific neuronal subpopulations.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between NP1131-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
Split Gal4 between NP3208-Gal4 and MB371B-Gal4 lines driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
NP3208-Gal4 line driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
Split Gal4 between NP5286-Gal4 and MB185B-Gal4 lines driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
NP5286-Gal4 line driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
Split Gal4 between NP7175-Gal4 and MB594B-Gal4 lines driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
NP7175-Gal4 line driving UAS-neurexin RNAi line, combined with dicer2.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
Mutant flies with nrx1 null allele. Flies also contain a mutation in the DNA repair gene mutagen-sensitive 309 (mus309) located at 86E17. Mutants were outcrossed for six generations with the w1118 strain.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
GCaMP expression with visualized alpha/beta neurons. To compare neural activities GCaMP6.0 was expressed in alphabeta neurons and Ca2+ imaging analysis was performed.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
Cameleon 2.1 expression with visualized alpha/beta neurons.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Compund heterozygous
Mutation:
Transheterozygote of the nrx-1 273 and d83 alleles together with Cac-GFP expressed under the MB247 Gal-4 driver.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Heterozygous
Mutation:
Mutant flies with nrx1 null allele. Flies also contain a mutation in the DNA repair gene mutagen-sensitive 309 (mus309) located at 86E17. Mutants were outcrossed for six generations with the w1118 strain.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Heterozygous
Mutation:
Transheterozygote of the 273 and d08766 alleles.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Heterozygous
Mutation:
Transheterozygote of the 273 and d83 alleles.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Hemizygous
Mutation:
Transheterozygotes of nrx1^273 and Df(3R) BSC685 that lacks the entire neuroexin gene.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
Mutant flies contain a transposon inserted in the 5' untranslated region of the neurexin gene generating a hypomorphic allele. Mutants were outcrossed for six generations with the w1118 strain.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source: Bloomington
Model Type:
Genetic
Model Genotype:
Homozygous
Mutation:
Mutant flies generated by impercise excision of a P-element using delta2-3 as a transposase source. Mutants were outcrossed for six generations with the w1118 strain.
Allele Type: Knockout
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between pdf-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between R15F02-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Model Type:
Genetic
Model Genotype:
Wild type
Mutation:
Cross between R35B12-Gal4 line and Uas-neurexin RNAi line.
Allele Type: Knockdown
Strain of Origin: Genetic Background: w^1118
ES Cell Line: Mutant ES Cell Line: Model Source:
Description: Nrx-1 mutants showed perturbed sleep patterns, as they sleep more at dusk and show a delayed daytime sleep profile compared to controls. Specifically, Nrx-1 mutants sleep significantly more during the night but not during the day compared to controls. Moreover, Nrx-1 mutants show increased sleep bout number during the night (but not the day) which is not significantly different in duration compared to controls.
Description: Nrx-1 mutants showed abnormal circadian rhythm compared to controls. Specifically, when in constant dark, Nrx-1 mutants showed longer free-running circadian periods and reduced rhythm strength, with no diffence in arrhythmicity, compared to controls.
Description: Nrx-1 mutants showed perturbed sleep patterns, as they sleep more at dusk and show a delayed daytime sleep profile compared to controls. Specifically, Nrx-1 mutants sleep significantly less during the day, but not during the night compared to controls. Additionally, Nrx-1 mutants show significantly higher number of sleep bouts both during the day and night which are significantly short (in min) compared to controls.
Description: Nrx-1 mutants showed perturbed sleep patterns, as they sleep more at dusk and show a delayed daytime sleep profile compared to controls. Specifically, Nrx-1 mutants sleep significantly more during the day but not the night compare to controls. Moverover, Nrx-1 mutants show increased sleep bout number both during the night and day, which are shorter in duration during the night but are not different during the day compared to controls.
Description: Nrx-1 mutants showed perturbed sleep patterns, as they sleep more at dusk and show a delayed daytime sleep profile compared to controls. Specifically, Nrx-1 mutants sleep significantly less during the day, but not during the night compared to controls. Additionally, Nrx-1 mutants show significantly higher number of sleep bouts both during the day and night which are significantly short (in min) compared to controls.
Description: Nrx-1 mutants showed abnormal sleep patterns compared to controls. Specifically, Nrx-1 mutants sleep significantly more during the day but not at night compared to controls. Moverover, Nrx-1 mutants show increased number of sleep bout both during the night and day which are shorted in duration during the night but are not different during the day compared to controls.
Description: Nrx-1 mutants showed abnormal sleep patterns compared to controls. Specifically, Nrx-1 mutants sleep significantly more at night but do not show change in sleep bout number or duration. During the day, Nrx-1 mutants sleep less and show significantly higher number of sleep bouts which are shorted in duration compared to controls.
Description: Nrx-1 mutants showed abnormal sleep patterns. Specifically, during the night, Nrx-1 mutants slept more and showed longer sleep bouts that did not differ in number from controls. During the day, Nrx-1 mutants did not differ from controls in sleep duration, sleep bout number or duration.
Description: Nrx-1 mutants showed abnormal sleep patterns. Specifically, Nrx-1 mutants slept more during the night and showed a decreased number of sleep bouts which were not different from controls. During the day, Nrx-1 mutants were not different in the amount of sleep, sleep bout number or duration compared to controls.
Description: Nrx-1 mutants show abnormal sleep patterns compared to controls. Heat-induced activation of Nrx-1 suppression resulted in altered sleep patterns during the recovery, including more sleep and increased sleep bout number but no change in sleep bout duration during the day.
Description: Nrx-1 mutants show abnormal sleep patterns compared to controls. Heat-induced activation of Nrx-1 suppression resulted in altered sleep patterns during the recovery, including more sleep, decreased sleep bout number but increased sleep bout duration during the night.
Description: Selective suppresion of nrx1 showed decreased ability to recover lost sleep compared to controls.
Exp Paradigm: Sleep deprivation for 12h overnight.